HIPK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1279465	0.86	2/20
SCHEMBL82741	0.51	2/20
Hydrochloric Acid (SCHEMBL72435)	0.50	2/20
SCHEMBL1046783	0.45	2/20
SCHEMBL1221248	0.41	2/20
SCHEMBL1163770	0.40	2/20
SCHEMBL294336	0.37	2/20
SCHEMBL1049256	0.36	2/20
SCHEMBL41607	0.34	2/20
Pictilisib (SCHEMBL190812)	1.00	1/20
Pi-103 (SCHEMBL258242)	1.00	1/20
SCHEMBL190513	0.95	1/20
SCHEMBL31205	0.88	1/20
SCHEMBL190211	0.87	1/20
SCHEMBL958991	0.84	1/20
SCHEMBL1087562	0.83	1/20
SCHEMBL190273	0.82	1/20
SCHEMBL190427	0.82	1/20
SCHEMBL1088395	0.82	1/20
SCHEMBL1300395	0.82	1/20

Clinical trials — most relevant to HIPK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Genetic Mechanisms and Additional Risk Factors Underlying Hip Dysplasia	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia	nan	UNKNOWN
Use of miRNAs in Growth Hormone Deficiency (GHD)	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer	nan	UNKNOWN
H19 in Acute Lymphoblastic Leukemia.	nan	UNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.	nan	UNKNOWN
Family Blood Pressure Program - GenNet Network	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HIPK1 binder may also engage these)

Protein	Name	Similarity
O88904	—	1.000	O88904 →
A4L9P5	—	1.000	A4L9P5 →
Q9QZR5	—	1.000	Q9QZR5 →
HIPK2	Homeodomain-interacting protein kinase 2	1.000	landscape →
Q9WUM7	—	0.999	Q9WUM7 →
Q9ERH7	—	0.992	Q9ERH7 →
HIPK3	Homeodomain-interacting protein kinase 3	0.990	landscape →
O88850	—	0.989	O88850 →
O70546	—	0.987	O70546 →
O14607	—	0.985	O14607 →
Q7Z3K3	—	0.985	Q7Z3K3 →
D3ZGB1	—	0.985	D3ZGB1 →
B2GUN4	—	0.984	B2GUN4 →
O94916	—	0.984	O94916 →
Q9WV30	—	0.984	Q9WV30 →
O88907	—	0.984	O88907 →
Q9H694	—	0.983	Q9H694 →
Q8N187	—	0.983	Q8N187 →
Q8C7R7	—	0.983	Q8C7R7 →
KDM6A	Lysine-specific demethylase 6A	0.983	landscape →
Q58CW6	—	0.983	Q58CW6 →
Q99PP7	—	0.983	Q99PP7 →
Q58FA4	—	0.982	Q58FA4 →
Q14119	—	0.982	Q14119 →
Q5ZKW8	—	0.982	Q5ZKW8 →
Q6B4Z3	—	0.982	Q6B4Z3 →
Q14B70	—	0.982	Q14B70 →
Q9QWH1	—	0.981	Q9QWH1 →
Q9QY01	—	0.981	Q9QY01 →
Q64127	—	0.981	Q64127 →